City of Hope Medical Center
Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited. This study seeks to develop a multi-omics-based liquid biopsy assay, especially focusing on ncRNAs (e.g. tsRNA, miRNA, circRNA, lncRNA, etc.) for accurate detection of early-stage HCC.
Liver cancer is a major global health challenge, ranking as the 5th leading cause of cancer-related deaths in the U.S. and 3rd worldwide, with hepatocellular carcinoma (HCC) accounting for \~75% of cases. Incidence has more than tripled since 1980, and death rates have risen by \~2% annually, highlighting the need for improved detection and treatment. Prognosis remains poor: over 50% of HCC cases are diagnosed at stage IV, with a 1-year survival below 30%, whereas early-stage HCC (stages I-II) can achieve up to 74% 5-year survival with curative interventions. Major risk factors include viral h…
Inclusion Criteria: * Adults aged 18 to 100 years. * A histologically confirmed diagnosis of hepatocellular carcinoma. * A clinically diagnosed as chronic liver disease, including chronic hepatitis or liver cirrhosis, without evidence of hepatocellular carcinoma. * Healthy volunteers without known liver disease or malignancy. * Received standard diagnostic and staging procedures as per local guidelines * Availability of blood or other biospecimens. * Ability to provide written informed consent. Exclusion Criteria: * Lack of or inability to provide informed consent * History of other active…
Comprehensive small RNA sequencing of serum or plasma-derived cf-tsRNAs to identify candidate biomarkers distinguishing HCC from NDC.
Construction of integrated cf- tsmiRNAs diagnostic classifier using machine learning
PCR-based validation of the tsRNA panel
Arctuva estimate
Verify or correct the compensation shown for this listing.